Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 84 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Amyloid-beta Clear all
Completed No phase listed Observational

Amyloid Beta and Cognition in Parkinson Disease

NCT01754168
View directory record Official record
Conditions
Parkinson Disease, Neurological Disorders
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
65 Years to 99 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Sep 4, 2026, 1:57 AM EDT
Completed No phase listed Observational

Study to Evaluate Amyloid in Blood and Imaging Related to Dementia

NCT03899844
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Dementia
Interventions
Blood collection, PiB PET/MRI, and cognitive testing
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
1,122 participants
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Sep 4, 2026, 1:57 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Curcumin and Retinal Study

NCT05774704
View directory record Official record
Conditions
Bioavailability, Gut Microbiome, Safety
Interventions
Low curcumin group, High curcumin group
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
40 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 4, 2026, 1:57 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

NCT06659549
View directory record Official record
Conditions
Geographic Atrophy of the Macula
Interventions
GAL-101, Placebo
Drug
Lead sponsor
Galimedix Therapeutics Inc
Industry
Eligibility
55 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Beverly Hills, California • Walnut Creek, California • Hagerstown, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 4, 2026, 1:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's

NCT01148498
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
solanezumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 90 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Sep 4, 2026, 1:57 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Sleep Trial to Prevent Alzheimer's Disease

NCT04629547
View directory record Official record
Conditions
Sleep, Alzheimer Disease
Interventions
Suvorexant 20 mg, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
65 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 4, 2026, 1:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.

NCT02309723
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Beta amyloid imaging
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
315 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 4, 2026, 1:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Brain Amyloid Using [11C]MeS-IMPY

NCT00407576
View directory record Official record
Conditions
Alzheimer's Disease, Healthy
Interventions
[11C]MeS-IMPY
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 4, 2026, 1:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sleep Quality and Amyloid-Beta Kinetics

NCT03077620
View directory record Official record
Conditions
Amyloid-beta
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
45 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 4, 2026, 1:57 AM EDT
Completed Early Phase 1 Interventional

Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People

NCT02669225
View directory record Official record
Conditions
Normal Physiology
Interventions
[18F]florbetaben
Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 4, 2026, 1:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction

NCT02063217
View directory record Official record
Conditions
Amyloid-beta
Interventions
Sodium Oxybate, Sleep deprivation
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Sep 4, 2026, 1:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain

NCT00287248
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[123I] IMPY & SPECT Imaging
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Sep 4, 2026, 1:57 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects

NCT00605046
View directory record Official record
Conditions
Alzheimer Disease
Interventions
SPECT scan
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced Sep 4, 2026, 1:57 AM EDT
Not listed No phase listed Observational

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

NCT06539169
View directory record Official record
Conditions
Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis, Creutzfeld-Jakob Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Early-Onset Alzheimer Disease, Ehlers-Danlos Syndrome, Huntington Disease, Gaucher Disease, GM1 Gangliosidosis, Myasthenia Gravis, Pompe Disease, Sickle Cell Disease, Transthyretin Amyloid Cardiomyopathy, Rare Diseases
Interventions
Not listed
Lead sponsor
xCures
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Altos, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Sep 4, 2026, 1:57 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease

NCT05138848
View directory record Official record
Conditions
Alzheimer Disease, Late Onset, Mild Cognitive Impairment, Sleep, Cognitive Change, Amyloid
Interventions
Time in Bed Restriction, Sleep Schedule
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years to 85 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 4, 2026, 1:57 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

NCT03522129
View directory record Official record
Conditions
Alzheimer Disease
Interventions
CT1812, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Sep 4, 2026, 1:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease

NCT00939822
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Simvastatin, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
40 Years to 72 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Fitchburg, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Sep 4, 2026, 1:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Postoperative Cognitive Decline, Inflammation, and Plasma Levels of Beta-amyloids

NCT00850928
View directory record Official record
Conditions
Postoperative Cognitive Dysfunction, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
65 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 4, 2026, 1:57 AM EDT
Completed Phase 2 Interventional Results available

Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients

NCT00857532
View directory record Official record
Conditions
Parkinson's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2013 · Synced Sep 4, 2026, 1:57 AM EDT
Completed Phase 3 Interventional

A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

NCT05463731
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Remternetug (IV), Remternetug (SC), Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
73
States / cities
Chandler, Arizona • Canoga Park, California • Carlsbad, California + 66 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 4, 2026, 1:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

NCT00556660
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[123I] AV-151
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 4, 2026, 1:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease

NCT00046358
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Lovostatin, Ibuprofen
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 4, 2026, 1:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Natural History of Amyloid Deposition in Adults With Down Syndrome

NCT01303133
View directory record Official record
Conditions
Down Syndrome
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
30 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 4, 2026, 1:57 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers

NCT00750282
View directory record Official record
Conditions
Alzheimer Disease, Amyloid Beta-Protein
Interventions
Florbetaben (BAY94-9172)
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
55 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Sun City, Arizona • Stanford, California • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 4, 2026, 1:57 AM EDT